

WHAT IS CLAIMED IS:

1. A polymorphous form of a mesylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.  
5
2. The polymorphic form of the mesylate salt according to Claim 1 that is characterized by an X-ray powder diffraction pattern having diffraction angles of: 10.67, 12.28, 17.88, 18.45, 21.21, 21.49, 22.68, 23.22, 23.37, 23.94, 27.12, 28.72, and 31.68.  
10
3. The polymorphic form of the mesylate salt according to Claim 2 having multiple diffraction peaks between 5° and 35° 2-theta and a melting endotherm of 233°C at a rate of 5°C per minute.  
15
4. The polymorphic form of the mesylate salt according to Claim 1 that is characterized by an X-ray powder diffraction pattern having diffraction angles of: 9.62, 13.61, 15.15, 15.69, 16.33, 16.58, 17.75, 18.07, 19.37, 19.62, 21.01, 21.23, 22.07, 22.35, 22.67, 22.87, 23.83, 25.05, 25.23, 27.63, and 30.47.  
20
5. The polymorphic form of the mesylate salt of Claim 4 having multiple diffraction peaks between 5° and 35° 2-theta and a melting endotherm of 232°C at a rate of 5°C per minute.  
25
6. A pharmaceutical composition that is comprised of a polymorphous form of the mesylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in accordance with Claim 1 and a pharmaceutically acceptable carrier.  
30
7. A pharmaceutical composition that is comprised of a polymorphous form of the mesylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in accordance with Claim 2 and a pharmaceutically acceptable carrier.  
35
8. A pharmaceutical composition that is comprised of a polymorphous form of the mesylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-

4-ylmethyl]-piperazine-1-carboxylic acid methylamide in accordance with Claim 4 and a pharmaceutically acceptable carrier.

5                   9.       A method of treating or preventing cancer in a mammal in need of such treatment which is comprised of administering to said mammal a therapeutically effective amount of the polymorphous form of the mesylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in accordance with Claim 1.

10                   10.       A method of treating cancer or preventing cancer in accordance with Claim 9 wherein the cancer is selected from cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung.

15                   11.       A method of treating or preventing cancer in accordance with Claim 9 wherein the cancer is selected from histiocytic lymphoma, lung adenocarcinoma, small cell lung cancers, pancreatic cancer, glioblastomas and breast carcinoma.

20                   12.       A method of treating or preventing a disease in which angiogenesis is implicated, which is comprised of administering to a mammal in need of such treatment a therapeutically effective amount of the polymorphic form of the mesylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in accordance with Claim 1.

25                   13.       The method in accordance with Claim 14 wherein the disease is an ocular disease.

30                   15.       The method according to Claim 13 wherein the ocular disease is retinal vascularization, diabetic retinopathy, age-related macular degeneration, retinal ischemia, or macular edema.

                  16.       A method of treating or preventing inflammatory diseases which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the polymorphic form of the mesylate salt of 4-[2-

(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in accordance with Claim 1.

17. A method according to Claim 16 wherein the inflammatory  
5 disease is selected from rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reactions.

18. A method of treating or preventing a tyrosine kinase-dependent  
10 disease or condition which comprises administering a therapeutically effective amount of the polymorphic form in accordance with Claim 1.

19. A method of treating or preventing bone associated pathologies  
selected from osteosarcoma, osteoarthritis, and rickets which comprises administering  
15 a therapeutically effective amount of the polymorphic form according to Claim 1.

20. The composition of Claim 6 further comprising a second  
compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 20 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 25 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor, and
- 10) another angiogenesis inhibitor.

21. The composition of Claim 20, wherein the second compound is  
30 another angiogenesis inhibitor selected from the group consisting of a tyrosine kinase inhibitor, an inhibitor of epidermal-derived growth factor, an inhibitor of fibroblast-derived growth factor, an inhibitor of platelet derived growth factor, an MMP inhibitor, an integrin blocker, interferon- $\alpha$ , interleukin-12, pentosan polysulfate, a cyclooxygenase inhibitor, carboxyamidotriazole, combretastatin A-4, squalamine,

6-O-chloroacetyl-carbonyl)-fumagillol, thalidomide, angiostatin, troponin-1, and an antibody to VEGF.

22. The composition of Claim 20, wherein the second compound is  
5 an estrogen receptor modulator selected from tamoxifen and raloxifene.

23. A method of treating cancer which comprises administering a  
therapeutically effective amount of the polymorphic form of the mesylate salt in  
accordance with Claim 1 in combination with radiation therapy.  
10

24. A method of treating or preventing cancer which comprises  
administering a therapeutically effective amount of the polymorphic form of the  
mesylate salt in accordance with Claim 1 in combination with a compound selected  
from:

- 15 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 20 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor, and
- 10) another angiogenesis inhibitor.

25 25. A method of treating cancer which comprises administering a  
therapeutically effective amount of the polymorphic form of the mesylate salt  
according to Claim 1 in combination with radiation therapy and a compound selected  
from:

- 30 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 35 6) a prenyl-protein transferase inhibitor,

- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor, and
- 10) another angiogenesis inhibitor.

5

26. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of the polymorphic form of the mesylate salt in accordance with Claim 1 and paclitaxel or trastuzumab.

10

27. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of the polymorphic form of the mesylate salt in accordance with Claim 1 and a GPIIb/IIIa antagonist.

15

28. The method of Claim 27 wherein the GPIIb/IIIa antagonist is tirofiban.

20

29. A method of reducing or preventing tissue damage following a cerebral ischemic event which comprises administering a therapeutically effective amount of the polymorphic form of the mesylate salt in accordance with Claim 1.

30. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of the polymorphic form of the mesylate salt of Claim 1 in combination with a COX-2 inhibitor.

25

31. A method of treating or preventing preeclampsia which comprises administering a therapeutically effective amount of the polymorphic form of the mesylate salt of Claim 1.

30

32. A method of treating or preventing tissue damage due to bacterial meningitis which comprises administering a therapeutically effective amount of the polymorphic form of the mesylate salt of Claim 1.

35

33. A method to treat or prevent endometrioses which comprises administering a therapeutically effective amount of the polymorphic form of the mesylate salt of Claim 1.

34. A method of treating or preventing diabetic retinopathy which comprises administering a therapeutically effective amount of the polymorphic form of the mesylate salt of Claim 1 in combination with a PPAR- $\gamma$  agonist.

5